Fantastic question because in the HABS-HD study that’s what we do as you know and what we have found over the last several years is that our general framework of Alzheimer’s being an A, T and an N sequence in progression holds up very well among non-Hispanic white individuals. But once we start looking among diverse populations, that sequence and that progression pattern is not necessarily the same...
Fantastic question because in the HABS-HD study that’s what we do as you know and what we have found over the last several years is that our general framework of Alzheimer’s being an A, T and an N sequence in progression holds up very well among non-Hispanic white individuals. But once we start looking among diverse populations, that sequence and that progression pattern is not necessarily the same. So what we’re seeing among certain populations, for example, is when amyloid is present, oftentimes it is neurodegeneration or vascular factors driving cognitive loss, not tau, and then others. So the sequences in these things are not necessarily the same, which I view as a wonderful opportunity for targeted precision medicine therapies, which is where the field is headed.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
